Close

Drug Research

Exeter University and Medicines Discovery Catapult collaborate on R&D drive

The collaboration will focus on identifying promising innovations that can be adopted through the industry in the ultimate hope of benefitting patients. The collaboration will combine the world-class research at the University of Exeter with MDC’s industry skills, discovery...

Moderna and Pfizer COVID Vaccines: The Comparison

Moderna Inc. on Monday declared that its vaccine was 94.5% effective. This came just after a week when Pfizer & its partner BioNTech SE had gone public to state that their vaccine is more than 90% effective. There is...

COVID-19 Genomics UK Consortium gets £12.2 million funding to expand whole genome sequencing of SARS-CoV-2 virus

The public will be better protected from COVID-19 with £12.2 million of funding awarded to potentially life-saving research into how the virus spreads and evolves through genome sequencing. The COVID-19 Genomics UK (COG-UK) Consortium will use the funding to expand...

FUJIFILM Cellular Dynamics and Lonza agree to expand the availability and use of induced pluripotent stem cell technology

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc. (Lonza, a leading global GMP iPSC manufacturer), have entered into a worldwide agreement. The agreement enables drug...

Pioneering research potentially reveals early detection of prostate cancer

Pioneering research conducted by University of Virginia in collaboration with Manchester UK based APIS Assay Technologies Ltd has discovered Hormone-Upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase (HULLK) is detectable in non-invasive prostate cancer patient samples. The breakthrough data provides...

Ypsomed collaborates with SCHOTT and Lonza to develop a comprehensive solution for combination products based on patch injectors

Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the pharmaceutical and biotechnology industry for the...

Stelis starts next phase of investment into its biologics manufacturing facility

Contract development and manufacturing organization (CDMO), Stelis BioSource, a division of Stelis Biopharma, has started the next phase of its continued investment program after having already invested more than $100 million into its facilities in Bangalore, India. The latest phase...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read